RT Journal Article
SR Electronic
T1 Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3117
OP 3123
DO 10.21873/anticanres.15800
VO 42
IS 6
A1 AKANE UNO
A1 SENRI YAMAMOTO
A1 HIROTOSHI IIHARA
A1 HIRONORI FUJII
A1 CHIYOKO MAKITA
A1 YOH HAYASAKI
A1 YUKINO UEDA
A1 MASAYA ITO
A1 MOTOKI TAKENAKA
A1 TOMOYASU KUMANO
A1 MINAKO MORI
A1 MOEKA YASUE
A1 HIROKO KATO-HAYASHI
A1 RYO KOBAYASHI
A1 KEN-ICHIROU MORISHIGE
A1 MASAYUKI MATSUO
A1 HIDEKI HAYASHI
A1 AKIO SUZUKI
YR 2022
UL http://ar.iiarjournals.org/content/42/6/3117.abstract
AB Background/Aim: Nausea and vomiting are two of the most distressing adverse events of cancer radiotherapy. The aim of this study was to examine the control rate and risk factors associated with nausea and vomiting in patients with cervical cancer receiving radiotherapy. Patients and Methods: This retrospective study examined patients with cervical cancer who received radiotherapy alone or with concomitant cisplatin. Patients who received radiotherapy alone were not administered antiemetic premedication, while patients who received radiotherapy with concomitant weekly cisplatin (40 mg/m2) were administered antiemetic therapy comprising granisetron and dexamethasone. Risk factors for non-complete response (CR) were identified using multivariate logistic regression analysis. Results: Multivariate analysis indicated that younger age and concomitant weekly cisplatin were significant factors associated with non-CR across 5 weeks of treatment in patients who received radiotherapy. The proportion achieving CR among younger patients (<65 years) who received radiotherapy alone or with concomitant cisplatin was significantly lower than that among older patients (≥65 years) (Concomitant cisplatin: 27% vs. 67%, p=0.049; Radiotherapy alone: 62% vs. 91%, p=0.166). However, the proportion of patients achieving CR across 5 weeks of treatment was insufficient in all groups except for those aged ≥ 65 years who received radiotherapy alone. Conclusion: Antiemetic prophylaxis should be considered for younger patients with cervical cancer undergoing radiotherapy alone. Further, neurokinin-1 receptor antagonist should be added to 5-hydroxytryptamine type-3 receptor antagonist and dexamethasone as antiemetic prophylactic therapy for patients with cervical cancer undergoing radiotherapy with concomitant weekly doses of 40 mg/m2 cisplatin.